P atients with end-stage restrictive heart disease (RCM) and hypertrophic cardiomyopathy (HCM) have a poor outlook, with a high risk of death due to heart failure or arrhythmias. [1] [2] [3] [4] Recently, continuous flow left ventricular assist devices (LVAD) have become a standard therapeutic option for patients with advanced dilated or ischemic cardiomyopathy who are failing maximal medical treatment [5] [6] [7] [8] and have been demonstrated to improve morbidity and mortality whether they are awaiting transplantation or as destination therapy. 7, 8 However, patients with end-stage RCM or HCM were not represented in these studies, and a detailed analysis describing the impact of continuous axial flow LVAD on their outcome has not been performed. In this study, we report the baseline characteristics, surgical outcome, and long-term impact of a continuous flow axial LVAD (Heart mate II, Thoratec, Pleasanton, CA) in 8 patients with advanced RCM and HCM and compare them to 75 patients with dilated and ischemic cardiomyopathy in our LVAD database.
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Methods
Patient Population
We identified all 83 consecutive patients who received continuous axial flow LVAD (Heart mate II, Thoratec, Pleasanton, CA) for either destination or bridge to transplant therapy between February 2007 and May 2010. All patients met the medical policy guideline of New York Heart Association (NYHA) class IIIb/IV heart failure.
We then divided the patients into 2 groups consisting of 8 patients with restrictive and hypertrophic cardiomyopathy (group 1: 4 HCM and 4 RCM) and 75 patients with severe dilated or ischemic cardiomyopathies (group 2: 38 ischemic heart disease, 37 dilated cardiomyopathy).
Clinical Demographic and Hemodynamic Data
Each patient's history and clinical examination were recorded at baseline by his or her physician at our institution. Preoperative demographic, clinical, echocardiographic, right heart catheterization, and laboratory data were abstracted from the medical records and our LVAD database. Laboratory data were collected 24 to 48 hours before surgery. Echocardiographic examinations were performed at 16 [7, 36] days, and hemodynamic catheterizations were performed at 4 [2, 9.7] days before surgery. The postsurgical hemodynamic measurements were performed just before removing the pulmonary artery catheter 4.5 [2.7, 6 .9] days after LVAD implantation. Data concerning adverse events, operative mortality, long term mortality, right heart failure and length of hospital stay were obtained by reviewing the medical records. Right ventricular stroke work index (RVSWI) was calculated using the hemodynamic data as previously described. 9 The study protocol was reviewed and approved by institutional review board at Mayo Clinic, Rochester, MN.
Events used as end points were (1) operative mortality defined as death at 30 days or during the index hospitalization; (2) right heart failure defined as the need for right ventricular assist device or duration of inotropic support more than 168 hours after surgery; (3) length of hospital stay until discharge from day of operation; and (4) total mortality throughout the follow-up.
Echocardiographic Measurements
Two-dimensional transthoracic echocardiography was performed in a standard manner using Sonos 5500 (Philips Medical Systems, Andover, MA), Sequoia 512 (Siemens, Mountainview, CA), or Vivid 7 (GE Medical Systems, Milwaukee, WI). Left ventricular diameters, ejection fraction, and mass were measured as recommended. 10 All patients had a complete 2-dimensional and Doppler echocardiographic study using multiple windows during the same examination. Mean pulmonary pressure was estimated using the mean of peak systolic tricuspid regurgitation velocity in end expiration. Right atrial pressure (RAP) was estimated by the inferior vena cava diameter and its response to inspiration as previously described. 11 We then used the modified Bernoulli formula (4ϫTRVmax 2 )ϩRAP. Right ventricular dysfunction, tricuspid, and mitral regurgitation severity were qualitatively graded in a 2-scale grading system (severe/non severe) using all apical views, RV inflow, parasternal long-axis, parasternal short-axis, and subcostal views. 12 Care was taken to obtain a true nonforeshortened apical-4 chamber view, oriented to obtain the maximum RV dimension, before making the right ventricular estimations. 10 RV function was then assessed by the lateral tricuspid annular motion method. 13, 14 
Myomectomy
Placing the inflow cannula in a small LV cavity can be challenging. The surgical technique is modified by first making a direct incision at the LV apex with a sharp pointed knife. Once the LV cavity is entered, the hole is enlarged with finger dilatation for inspecting the LV cavity anatomy. Once the anatomy is delineated, we proceed with coring out the LV apex with the Heart Mate II dedicated coring knife and perform additional LV myectomy as needed to create adequate space for the inflow cannula, in keeping with the basic principle of positioning the inflow cannula alignment with the long axis of the LV pointing toward the mitral valve ( Figure 1 ).
Statistical Analysis
Data were checked visually looking for heavy tails or outliers and analyzed using the Shapiro-Wilk test for normality. Continuous normally distributed parameters were presented as meanϮSD and compared using the Student t test or paired t test. Ordinal and/or nonnormally distributed data were presented by median, first and third quartiles and compared using the exact nonparametric Wilcoxon rank sum or Wilcoxon signed rank test. Categorical data were compared between groups using the Fisher exact test. McNemar exact test was used to compare differences in proportions over time. Unadjusted Cox proportional hazards were used to analyze the association of the presence of R/H cardiomyopathy with mortality rates with calculation of hazard ratios (HR) and confidence intervals.
Survival distributions were calculated according to the KaplanMeier method and compared by means of the log-rank test. Patients were censored at the time of last follow-up or at the time of heart transplant. All probability values were 2-sided, and values of Ͻ0.05 were considered to indicate statistical significance. All data were analyzed with the JMP System software version 8.0 or SAS (for the exact Wilcoxon tests) (SAS Institute, Inc, Cary, NC). All authors participated in designing the study, collecting and analyzing data, and drafting and revising the manuscript. The percentage of patients considered destination therapy was significantly higher in the DCM/ICM group as compared with the RCM/HCM group. To assess the possibility of a selection bias data were reanalyzed in the bridge to transplant patients only by excluding all the destination therapy patients ( Table 2 shows the 30-day postoperative outcomes in all patients and divided into the groups. In the operating room, 
Results
Baseline Characteristics
Postoperative Outcomes
Clinical Outcomes
Immediate Hemodynamic Measurements
After surgery, right atrial pressure was increased and LVAD flows were lower in patients with RCM or HCM compared with patients with dilated or ischemic cardiomyopathy (18 [15, 20] mm Hg versus 12 [9, 15] We compared the hemodynamic measurements before surgery with those performed immediately before taking out the pulmonary artery catheter (4.5 [2.7, 6 .9] days after surgery) ( . Myomectomy performed to enable appropriate placement of the inflow cannula to allow proper blood flow into it in a patient with hypertrophic cardiomyopathy. A, Direct incision at the left ventricular (LV) apex with a sharp-pointed knife is performed followed by finger dilatation for inspection LV cavity anatomy. B, Once the anatomy is understood, we proceed with LV myectomy as needed to create a space for the inflow cannula. C, Excess myocardial tissue is removed and sent to pathological examination. D, We then proceed with anchoring the apical sewing ring in the apex. E, Transesophageal echocardiographic mid esophageal 4-chamber view before bypass showing the markedly thickened LV and right ventricle (RV). Interatrial septum is deviated to the left, suggesting higher left atrial (LA) than right atrial (RA) pressure. Note the significantly thickened apex interfering with inflow cannula insertion (arrow). F, After LV assist device insertion, the results of extensive apical myectomy allow insertion of the inflow cannula (white arrows). LVAD indicates left ventricular assist device; I, ischemic heart disease; D, dilated cardiomyopathy; R, restrictive heart disease; H, hypertrophic cardiomyopathy; NYHA, New York Heart Association; IABP, intra-aortic balloon pump; MR, mitral regurgitation; TR, tricuspid regurgitation; PVR, pulmonary vascular resistance in Wood Units; and RV, right ventricle; n indicates number of patients.
*E/eЈ indicates ratio of E velocity of mitral inflow to early diastolic relaxation tissue velocity of medial annulus. †Deceleration time of early mitral inflow. ‡Estimation of right atrial pressure using the inferior vena cava method. 
Clinical, Laboratory, and Echocardiographic Parameters
We compared the clinical, laboratory, and echocardiographic parameters before surgery with those performed 3 months after surgery (Table 3 ). There was a significant decrease in the proportion of patients in NYHA class ϾIII (100% (8) 
Prognosis
Median (min, max) follow-up duration after surgery was 166 [1, 1044] days. Eighteen patients (21.7%) died, and 11 patients had their LVAD explanted for heart transplantation during the follow-up period. Fifty-four patients (65.0%) remained event-free at the end of follow-up. The survival rates were 77.4Ϯ5.5% and 62.6Ϯ9.2% at 1 and 2 years, respectively. The 1-year survival rate was not different between patients with RCM or HCM, and patients with dilated or ischemic cardiomyopathy 87.5% [95% confidence I indicates ischemic heart disease; D, dilated cardiomyopathy; R, restrictive heart disease; H, hypertrophic cardiomyopathy; RVAD, right ventricular assist device; RA, right atrium; PA, pulmonary artery; LOS, length of stay from surgery to discharge; and RV, right ventricle.
*Bleeding requiring blood transfusion more than 24 hours after surgery. †Mechanical ventilation for more than 1 week or need for tracheostomy. ‡Hemodynamically significant arrhythmia or requiring cardioversion. §Renal failure requiring dialysis, increase in creatinine to Ͼ2 or by Ͼ50% from baseline. ¶Any stroke, brain hemorrhage, or hyperperfusion injury. Liver enzymes Ͼ300 or bilirubin Ͼ5.0 after surgery. **Any embolic event after surgery. † †The hemodynamic data represent the last measurement before taking out the pulmonary artery catheter; pump flow and rpm by the LVAD monitor before discharge or death. After exclusion of the destination therapy patients, survival of the bridge to transplant patients remained comparable between the 2 groups; however, because of the small number of patients, lack of statistical power and a relatively short period of follow-up, definitive conclusions cannot be reached. 
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Outcome of Restrictive or Hypertrophic CMP Patients on the Transplant Waiting List
To compare the outcomes of patients with RCM/ HCM on the transplant waiting list with and without the use of LVAD therapy, we analyzed data in 12 consecutive patients (3 with senile amyloidosis, 5 with familial amyloidosis, 1 with idiopathic restrictive cardiomyopathy, and 3 with hypertrophic cardiomyopathy) who were being bridged to transplant on inotropes. There were no significant differences in the baseline characteristics of these patients as compared with the LVAD-treated RCM/HCM group ( 
Discussion
This study is the first to report that continuous axial flow pumps can be used in patients with end-stage RCM or HCM with acceptable morbidity and mortality. However, these patients can have persistent right heart failure likely due to primary involvement of the right ventricle from the underlying cardiomyopathic process and significant preexistent pulmonary hypertension, the latter appears to improve as shown by RVSP measurement by echocardiography during follow-up. There also are technical challenges with implantation of LVAD in patients with thickened left ventricular walls and small left ventricular chamber size. Line infections appeared to be significantly more common in patients with RCM or HCM and seem to be related to the prolonged inotropic use.
The recent LVAD trials were focused on subjects with end-stage dilated and ischemic cardiomyopathy. Patients with advanced restrictive or hypertrophic cardiomyopathy were not represented in these trials. 15, 16 The medical treatment options for patients with end-stage RCM or HCM are limited. Patients are prone to digoxin toxicity, hypotension occurs frequently with vasodilators, and diuretics often result in prerenal azotemia due to the steep LV pressure-volume relationship. These patients are at a high risk of death due to progressive heart failure or arrhythmias, 1-4 particularly those with higher NYHA class. 17 The only option available for these patients to improve survival was heart transplantation. However, due to a long waiting time on the transplant list, LVAD indicates left ventricular assist device; R, restrictive heart disease; H, hypertrophic cardiomyopathy; NYHA, New York Heart Association; RA, right atrium; and PA, pulmonary artery; n indicates number of patients.
*E/eЈ, ratio of E velocity of mitral inflow to early diastolic relaxation tissue velocity of medial annulus. †Deceleration time of early mitral inflow. ‡Comparison to the LVAD restrictive/hypertrophic cardiomyopathy group.
many patients develop irreversible pulmonary hypertension and mortality is high due to limited options that enable successful bridging to transplant. 17 The preliminary results reported in this study suggest that LVAD therapy may improve outcomes in patients with end-stage restrictive or hypertrophic cardiomyopathy and can be considered as a bridge to transplant. We found that the long-term survival in this small cohort of patients was comparable to the LVAD patients with end-stage dilated or ischemic cardiomyopathy 8, 15 and seemed to have been improved as compared with the reported natural history of end-stage RCM or HCM with medical therapy [1] [2] [3] [4] 6, 17 or with patients with RCM or HCM awaiting transplant on inotropes. Conclusions regarding survival should be made with caution given that this single center experience was not powered to elucidate differences in survival but simply demonstrates the feasibility of using LVAD therapy to successfully treat patients with end-stage RCM/HCM with comparable outcomes to those with DCM/ICM.
The patients with restrictive or hypertrophic cardiomyopathy had significantly more infections. Importantly, the total length of stay was unaffected by these events and was comparable to LVAD patients with dilated or ischemic cardiomyopathy in our experience. The increased rate of infection observed was largely due to central venous catheter related infections that may have been related to the trend for longer duration of inotropic support.
Perhaps patients with end-stage RCM or HCM were not represented in previous LVAD trials 8, 15 due to perceived technical obstacles that could occur with a smaller left ventricular chamber size and uncertain clinical outcomes. Our experience suggests that LVAD implantation is technically feasible with the possible need for myomectomy during the index surgery in select patients (Figure 1 ). LVAD therapy in these patients entails a higher risk for postoperative right ventricular dysfunction (Table 3 and Figures 3 and 4) , but this appears to improve with time as evidenced by transient requirement of inotropes, improvement in functional status, and the echocardiographic evaluation 3 months after surgery ( Table 3 ). The likely explanation of persistent right heart failure in patients with RCM/HCM is the presence of primary myopathic involvement of the right ventricle and the significant preexistent pulmonary hypertension that afflicts these patients. However, RV function after LVAD support in these patients actually improves with time as evidenced by successful weaning of inotropes and an improvement in right atrial pressures. This is probably related to improvement in RV afterload as shown by a decrease in RVSP measurements by echocardiography during follow-up. These findings suggest that secondary pulmonary hypertension plays an important role in the right heart failure symptoms observed in these patients.
RV Dysfunction and "Suck-Down Events"
LVAD patients with RCM and HCM had evidence of worse RV dysfunction compared with patients with dilated or ischemic cardiomyopathy after implantation suggested by increased right atrial pressure, decreased pump flow, and trend for increased duration of inotropic support in the postoperative period after LVAD implantation. If right ventricular output decreases, it may cause a decrease in left ventricular cavity size and a shift of the interventricular septum to the left. This in turn further impairs RV function and increases TR severity, diminishing the already compromised right ventricular output. This worsening spiral may cause the septum to encroach on the inflow cannula increasing inflow velocities ( Figure 3 ) and drastically decreasing LVAD preload, sometimes referred to as "suck-down event." The HeartMate II has a built-in algorithm for detection of "suck-down events" (automatically dropping to the low speed limit). In patients with RCM or HCM, the ventricles are sometimes so stiff that we were able to document "suck-down events" of the left atrium in 1 of our patients. The pump was unable to detect the collapse of the left atrium, culminating in very low LVAD output requiring careful manipulation of rpm under echocardiographic guidance, high fluid volume, and cautious use of inotropes to enable filling of the left side of the heart (Figure 4 ). The possibility of left atrial suction, which can be missed by the Heart Mate II suction detection safe mechanism, should be considered, and judicious increments of LVAD rpm should be performed only under strict echocardiographic guidance. Postsurgical inotropic support for right ventricular dysfunction should take into account the relatively preserved contractility of the left ventricle and the possibility for appearance of a dynamic LVAD inflow cannula obstruction. Our experience shows that permissive use of fluids (improving RV preload) and ␤-blockers (prolonging diastolic filling period) combined with low doses of milrinone (improving RV contractility, and decreasing RV afterload) improved right ventricular output without deleterious effects on LV contractility.
Myomectomy and Inflow Cannula Obstruction
During LVAD implantation in a small, restricted ventricle, technical refinements in the surgical procedure may need to be considered. Proper, and sometimes extensive myomectomy, may need to be performed before placement of the inflow cannula, especially in patients with hypertrophic cardiomyopathy and thickened apex or mid ventricle (performed in 2 of 4 of our hypertrophic cardiomyopathy patients) (Figure 1) . If not performed, thick hypercontractile muscle bundles may obstruct the inflow cannula, especially during systole when LVAD output is expected to be maximal, decreasing pump flows.
Conclusion
Continuous flow axial LVAD therapy may be feasible in patients with end-stage restrictive or hypertrophic cardiomyopathy and may prove to become a useful option to treat these patients who have end-stage heart failure. However, the present preliminary report lacks the statistical power to make conclusions regarding survival and prospective clinical trials will be required to assess whether LVAD therapy should be used routinely in this challenging group of patients.
Clinical Implications
Patients with end-stage restrictive or hypertrophic cardiomyopathy have a dismal prognosis. The only option that may increase survival in these patients is heart transplantation. However, because of continued donor shortages, a long transplant waiting time, and development of irreversible pulmonary hypertension, many of these patients die of irreversible heart failure and incur high mortality. Continuous-flow LVADs have been recognized to improve outcomes in patients with advanced dilated or ischemic cardiomyopathy who are failing maximal medical treatment; however, patients with end-stage RCM or HCM were not represented in these LVAD trials. This is the first report to show the feasibility of continuous axial flow pumps in patients with end-stage RCM or HCM. However, these patients can incur more right heart failure and central venous catheter-related infections. There are also numerous technical challenges with implantation of LVAD that are unique to these patients including the need for myomectomy to enable inflow cannula implantation and the increased risk for "suckdown" events. This single-center experience lacks the statistical power to make conclusions regarding survival, and this data cannot necessarily be extrapolated to other centers. This feasibility study should prompt prospective clinical trials or a national registry to assess whether LVAD therapy can be used routinely as destination therapy or bridge to transplantation in this challenging group of patients.
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